Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACSTNASDAQ:EQNASDAQ:MDNACVE:WMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsEQEquillium$0.35-10.2%$0.41$0.33▼$1.50$12.39M1.94433,899 shs1.11 million shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsWMDWeedMDC$0.28-1.8%C$0.28C$0.23▼C$0.99C$67.82MN/A766,591 shs271,436 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%-7.72%-2.20%EQEquillium0.00%-8.68%-11.03%-54.03%-51.20%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%WMDWeedMD0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti PharmaN/AN/AN/AN/AN/AN/AN/AN/AEQEquillium2.8401 of 5 stars3.25.00.00.02.21.70.6MDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AWMDWeedMDN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideEQEquillium 2.33Hold$3.00764.55% UpsideMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideWMDWeedMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ACST, MDNA, EQ, and WMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/AEQEquillium$30.41M0.41N/AN/A$0.64 per share0.54MDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AWMDWeedMDC$27.53M2.46C$0.08 per share3.27C$0.34 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/AEQEquillium-$13.34M-$0.39N/AN/AN/A-10.05%-20.68%-10.77%8/6/2025 (Estimated)MDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/AWMDWeedMDN/A-C$0.42N/A∞N/AN/AN/AN/AN/ALatest ACST, MDNA, EQ, and WMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AWMDWeedMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86EQEquilliumN/A3.043.04MDNAMedicenna TherapeuticsN/A9.579.57WMDWeedMD95.633.461.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%EQEquillium27.05%MDNAMedicenna Therapeutics12.38%WMDWeedMDN/AInsider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%EQEquillium31.60%MDNAMedicenna Therapeutics33.10%WMDWeedMDN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableEQEquillium4035.72 million24.70 millionNot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableWMDWeedMD628246.62 millionN/ANot OptionableACST, MDNA, EQ, and WMD HeadlinesRecent News About These CompaniesENTG:CA Entourage Health Corp.October 19, 2024 | seekingalpha.comHurricane Helene by the numbers: Catastrophic destruction covers 400 milesOctober 4, 2024 | abcnews.go.comWMDH WMD Holdings Group, Inc.September 28, 2024 | seekingalpha.comEthics and Weapons of Mass DestructionAugust 8, 2024 | cambridge.org'Truth about WMD will finally emerge'March 4, 2024 | dailymail.co.ukNo cabinet submission on costs, benefits, implications of going to war in IraqJanuary 3, 2024 | theaustralian.com.auBlair: 'Saddam still has weapons of mass destruction'October 5, 2023 | dailymail.co.ukBush administration retreats on WMD claimAugust 29, 2023 | namibian.com.naMissing WMD ‘hurting war on terror’August 29, 2023 | namibian.com.naWeapons of Mass Destruction and the ethics of their usageAugust 17, 2023 | arstechnica.comRussia used sabotaged dam as ‘weapon of mass destruction’ says UkraineJune 12, 2023 | politico.euUS, South Korea issue fresh North Korea sanctions on 'illicit' IT workforceMay 27, 2023 | asahi.comMalaysia Gets Tough on WMDMay 27, 2023 | thediplomat.comInterpol Tackles WMD TerrorismMay 21, 2023 | thediplomat.com'Weapons of mass destruction found'May 20, 2023 | dailymail.co.ukChemical Weapons are NOT WMDsMay 17, 2023 | thediplomat.comThe Next Financial WMD?May 14, 2023 | thestreet.comThe Week in Weed – May 6, 2023 - StratCannMay 6, 2023 | news.google.comWMD in Iraq: Evidence and ImplicationsApril 28, 2023 | medscape.comWhat happened when WMD experts tried to make the GPT-4 AI do bad thingsApril 2, 2023 | thebulletin.orgNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?By Gabriel Osorio-Mazilli | May 22, 2025View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?Top 4 ETFs for China Exposure After Tariff Relief By Nathan Reiff | May 17, 2025View Top 4 ETFs for China Exposure After Tariff Relief ASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyBy Jeffrey Neal Johnson | June 10, 2025View ASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyThis Banking Giant Just Got a $90 Price Target UpgradeBy Gabriel Osorio-Mazilli | June 6, 2025View This Banking Giant Just Got a $90 Price Target Upgrade3 Dividend Stocks Just Hiked Payouts 10%+ and Beat the MarketBy Leo Miller | May 27, 2025View 3 Dividend Stocks Just Hiked Payouts 10%+ and Beat the MarketACST, MDNA, EQ, and WMD Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Equillium NASDAQ:EQ$0.35 -0.04 (-10.22%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.58%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.WeedMD CVE:WMDC$0.28 -0.01 (-1.79%) As of 07/15/2021WeedMD Inc. produces, distributes, and sells medical-grade cannabis in Canada. It offers dried cannabis, cannabis plants and seeds, cannabis oil, edibles, extracts and topicals, and others, as well as cannabis flower products. The company sells its products directly to medical patients and strategic relationships across the seniors' market, as well as through supply agreements with Shoppers Drug Mart and six provincial distribution agencies under the Color Cannabis, Saturday, Starseed, and WeedMD brand names. WeedMD Inc. is headquartered in Aylmer, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
